Enzalutamide and blocking androgen receptor in advanced prostate cancer: lessons learnt from the history of drug development of antiandrogens

Enzalutamide and blocking androgen receptor in advanced prostate cancer: lessons learnt from the history of drug development of antiandrogens

Yusuke Ito, Marianne D Sadar Genome Sciences Centre, BC Cancer, Vancouver, BC, Canada Abstract: Enzalutamide is a nonsteroidal antiandrogen for the treatment of metastatic castration-resistant prostate cancer (mCRPC) both before and after chemotherapy. Enzalutamide is more effective than its predece...

Full description

Bibliographic Details
Main Authors: Ito Y, Sadar MD
Format: Article
Language:English
Published: Dove Medical Press 2018-02-01
Series:Research and Reports in Urology
Subjects:
prostate cancer
enzalutamide
antiandrogens
Cmin
trough
pharmacology
cross- resistance
clinical trials
PSA response
ralaniten
EPI-002
Online Access:https://www.dovepress.com/enzalutamide-and-blocking-androgen-receptor-in-advanced-prostate-cance-peer-reviewed-article-RRU

Internet

https://www.dovepress.com/enzalutamide-and-blocking-androgen-receptor-in-advanced-prostate-cance-peer-reviewed-article-RRU

Similar Items